Apple a fait face à un revers dans une décision récente concernant un outil de santé sur l'Apple Watch. Malgré ses tentatives de refonte de l'outil, Apple n'a pas réussi et dispose désormais de trois options : accorder une licence pour les brevets de Masimo, attendre que les brevets expirent en août 2028 ou gagner un appel devant le tribunal. Dans les documents judiciaires […]
In court documents reviewed by AppleInsider, Apple made significant claims to challenge the ITC’s original ruling. They argued that Masimo’s patents were invalid and that Masimo had no plans to develop its own smartwatch with a pulse oximeter, contrary to previous testimonies.
Apple criticized the ITC’s decision, stating that it was based on faulty patent judgments that have since been invalidated. They also pointed out that Masimo rushed to file new patent claims after Apple introduced the Apple Watch Series 6, suggesting a strategic move against them.
Regarding Masimo’s claim about producing their own smartwatch, Apple revealed that it was based on CAD drawings of a non-existent “Masimo Watch.” This admission weakened Masimo’s case further.
In conclusion, Apple hopes for a reversal or remand of the ITC decision. They believe that the ruling was unjustified and based on faulty grounds. The tech giant is determined to fight for their right to continue importing certain models of the Apple Watch without restrictions.
